Avicanna (TSE:AVCN) has released an update.
Avicanna Inc., a biopharmaceutical company, has launched a significant study on medical cannabis with 1,000 Canadian patients to investigate its effects on conditions like pain, sleep, anxiety, depression, and epilepsy. Led by Dr. Hance Clarke, the study will leverage MyMedi.ca’s resources to enhance research and potentially integrate cannabis into the standard of care. The initiative is also supported by various licensed producers, including Avicanna’s own RHO Phyto product line.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
